iBio, Other Monday, November 16, 2026 +0.10 Neutral

iBio Shares Weight-Loss Data From Activin E Program at ObesityWeek

iBio reported 2.3% body weight loss in obese Primates for its Activin E antibody, IBIO-610, as well as data on its amylin program, underscoring progress for its obesity-focused pipeline.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed